Antiproteases and Down’s syndrome in an Australian population*

H McPhee, R Ananthakrishnan,† and L I Taft

From the Department of Genetics, University of Melbourne, Parkville, Victoria 3052; and Department of Pathology, Mercy Maternity Hospital, Melbourne, Victoria 3000, Australia

SUMMARY α₁-antitrypsin phenotypes and α₂-macroglobulin concentrations were determined for an Australian population of 286 Down’s syndrome patients, 296 newborn babies, and 193 patients with non-specific mental retardation. There was no significant difference between the groups in the distribution of the phenotypes or level of heterozygosity. The phenotypic frequencies were 89.5% PiMM, 8.0% PiMS, and 1.0% PiMZ among controls. The mean α₂-macroglobulin concentrations were investigated and it was shown that PiMZ phenotypes had a higher concentration, 2.67 ± 0.27 g/l (newborns) and 2.74 ± 0.32 g/l (Down’s syndrome), in comparison with PiMS, PiSS, and PiMM.

The increased frequency of heterozygotes for α₁-AT phenotypes among mothers of children with chromosomal aberrations noted by Aarskog and Fagerhol1 suggested a relationship between α₁-AT phenotypes and chromosomal abnormalities. This observation has been extended by Kueppers et al2 who noted an excess of heterozygotes in the combined parental group as well as among patients with chromosomal abnormalities. Similarly, Fineman et al3 noted an increased frequency of heterozygotes among Down’s syndrome patients in the older mothers groups; distribution of α₁-AT phenotypes among parents were not determined. However, Arnaud et al4 were unable to observe any significant differences in the distribution of α₁-AT phenotypes between Down’s syndrome patients and controls.

In view of these contradictions, we report the results of investigations on α₁-antitrypsin phenotypes as well as quantification of α₂-macroglobulin in Down’s syndrome, non-specific mental retardation, and in controls for an Australian population.

Materials and methods

α₁-antitrypsin was phenotyped by isoelectric focusing in thin layers of polyacrylamide gels using the method of Kueppers,5 with minor modifications, using LKB ampholines in the pH range of 4 to 6. The gel was prerun at a constant 25 mA for one hour. On completion of the run, the protein bands were precipitated in 10% trichloracetic acid overnight and the gel washed in two rinses of distilled water. Proteins were stained using 0.25% amido black in 7% acetic acid and destained in 7% acetic acid. Rare phenotypes were identified by comparison with standards obtained through the courtesy of Dr M Fagerhol, Oslo, Norway.

Quantification of α₁-AT and α₂-MG

Radial immunodiffusion was used to determine α₁-antitrypsin and α₂-macroglobulin concentrations in sera. The antisera were commercially available from Kallestad and Berhingwerke standard plasmas of known α₁-antitrypsin and α₂-macroglobulin concentrations (g/l) were used as controls. Samples for α₂-macroglobulin levels were diluted 1:2 and samples for α₁-antitrypsin levels were diluted in accordance with their phenotype. ZZ sera were used undiluted, SS, SZ, and MZ sera were diluted 1:10, and all others were diluted 1:20. The plates were left at 4°C for 48 hours in the case of α₁-AT and 72 hours for α₂-MG and the resulting precipitin ring diameters were measured. A standard graph was constructed, using the control sera of concentration (g/l) vs the squares of the diameter of the precipitin ring. Results for the other samples were read off the graph using the same technique.
TABLE 1 Phenotypic distribution of $\alpha_1$-AT in Australian populations

<table>
<thead>
<tr>
<th>Samples</th>
<th>M</th>
<th>MS</th>
<th>MZ</th>
<th>GM</th>
<th>FM</th>
<th>FF</th>
<th>SS</th>
<th>SZ</th>
<th>Others</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cord blood</td>
<td>89-5%</td>
<td>8-0%</td>
<td>1-0%</td>
<td>1-0%</td>
<td>—</td>
<td>—</td>
<td>1-0%</td>
<td>—</td>
<td>1 MN</td>
<td>296</td>
</tr>
<tr>
<td>Observed</td>
<td>265</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expected</td>
<td>252.9</td>
<td>25.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\chi^2$</td>
<td>0-60</td>
<td>0-80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Down's syndrome</td>
<td>88.8%</td>
<td>8-7%</td>
<td>1.4%</td>
<td>0.35%</td>
<td>0.35%</td>
<td>0.35%</td>
<td>—</td>
<td>—</td>
<td></td>
<td>286</td>
</tr>
<tr>
<td>Observed</td>
<td>254</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expected</td>
<td>269.4</td>
<td>23.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\chi^2$</td>
<td>0-09</td>
<td>0-007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-specific retardation</td>
<td>89.6%</td>
<td>8-7%</td>
<td>1-2%</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0.5%</td>
<td>0.5%</td>
<td>1 MP</td>
<td>193</td>
</tr>
<tr>
<td>Observed</td>
<td>173</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expected</td>
<td>181.4</td>
<td>16.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\chi^2$</td>
<td>0-4</td>
<td>0-005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pool</td>
<td>89-3%</td>
<td>9-0%</td>
<td>1-2%</td>
<td>0.5%</td>
<td>0-1%</td>
<td>0-1%</td>
<td>0-5%</td>
<td>0-1%</td>
<td>1 MN</td>
<td>775</td>
</tr>
<tr>
<td>Observed</td>
<td>692</td>
<td>61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expected</td>
<td>728.5</td>
<td>65.6</td>
<td>8.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\chi^2$</td>
<td>1-8</td>
<td>0-30</td>
<td>0-01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SampLes
Cord blood samples had been previously collected from the Mercy Maternity Hospital, Melbourne. Sera from patients with Down's syndrome and non-specific mental retardation were obtained as has been described by Ball et al. and Brackenridge et al.7

Results
The distribution of the $\alpha_1$-AT phenotypes is given in table 1. It is obvious that there is no significant difference in the frequency of the common phenotypes MM and MS in the three groups. The distribution of the two phenotypes MM and MS are found to be in Hardy-Weinberg equilibrium. The allele frequencies of $P^m$, $P$, and $P^2$ are given in table 2. This table shows the differences in these three alleles between Australian, British, and American populations. Although the $z$ allele frequency is considerably higher in the American population, the $s$ allele frequency is lower. The allele frequencies for the Australian and British populations are very similar. The only difference in the distribution of $\alpha_1$-AT phenotypes is the occurrence of rare phenotypes GM, FM, and FF at a frequency of 1-05% among Down's syndrome patients. There was no difference in the frequency of total heterozygosity (11.5% among Down's syndrome, 10.9% among non-specific mental retardation patients, and 11% among newborn infants).

Table 3 shows the results of quantitative estimation of $z$-macroglobulin and $\alpha_1$-AT in newborn children and in Down's syndrome. The mean $\alpha_1$-AT concentration among newborn children was 2.84 ± 0.88 g/l, while that of the Down's syndrome group was 3.06 ± 0.46 g/l. In contrast to this, however, the mean concentration of the $z$-macroglobulin was 2.96 ± 0.56 g/l among newborn children, while it was 2.25 ± 0.50 g/l among Down's syndrome patients.

Discussion
The allele frequencies found in this Australian pooled sample compare very favourably with those of Cook8 for a British population. The allelic frequencies for Australian and British populations are much more similar than those of Rynbrandt et al.9 for an American population. This is not surprising when you consider the ethnic backgrounds of the countries involved.

Earlier investigations had shown an increased
frequency of heterozygotes among patients with sex chromosome mosaicism. For example, Aarskog and Fagerhol detected two MS among 14 patients (14%) which was higher than the 8 to 9% frequency of MS reported for Caucasian populations. However, these authors were unable to decide whether the increased frequency was among the paternal or maternal group or both. Kueppers et al noted an increased frequency of heterozygotes among 21 patients with sex chromosome mosaicism (23.8%); this increase was noted in both the maternal and paternal group. Fineman et al observed that in Down's syndrome patients whose mothers were 35 and over at the time of their birth, there was an increased frequency of heterozygotes for α1-AT phenotypes.

The lack of an increase in heterozygosity for α1-AT variants in the current study contradicts the findings of Fineman et al. It may be argued that the discrepancy could be attributed to the lack of information regarding maternal age. This, however, is unlikely to provide a satisfactory explanation since a major proportion of Down's syndrome children are found among progeny of older mothers, while those of younger mothers constitute only a small proportion of the total. Similarly, Arnaud et al were unable to find an increased frequency of α1-AT heterozygotes among Down's syndrome children. Also, our sample sizes are considerably larger than those of Fineman et al as against 60 Down's syndrome patients.

Evans et al reported differences in the relative concentrations of proteins in the electrophoretic bands 4 and 6, numbering being in order of decreasing anodal mobility. Among newborn children, the relative anodal bands, notably band 4, are more intense, the pattern being reversed after birth. The control population consisted of newborn children and a similar pattern was observed, even though isoelectric focusing rather than starch gel electrophoresis was used. These changes may represent developmental changes in the relative activities of multiple molecular forms of α1-antitrypsin. The significance of these changes is yet to be elucidated.

α2-macroglobulin, one of the antiproteases found in comparable concentrations in human serum, is capable of inhibiting trypsin in common with α1-AT. Therefore, it seemed worthwhile to study a wide variety of proteolytic enzymes, including the α2-macroglobulin concentration, among Down's syndrome patients as well as to investigate the possible influence of α1-AT phenotypes on α2-MG concentrations. α2-macroglobulin is age-dependent, with the concentration in cord blood varying between 2 and 4 g/l, which is 50% higher than the normal mean adult level. The Down's syndrome patients, mean age 40 years, were found to have a higher quantity of α2-MG which is in keeping with other published studies. The phenotypes MZ and MS did show differences from that of MM (table 3) and the SS phenotypes exhibited α2-MG levels similar to those of MS and MZ. In both newborn infants and Down's syndrome patients, the MS phenotype was lower in α2-macroglobulin concentration than the MZ phenotype. This may be the result of sample size effect, as the number of subjects in both the MS and MZ classes are small compared to the number in the MM classes. Since the frequency of ZZ phenotypes is very low among normal populations, we had no access to them among these patients and controls, so we used Pi heterozygotes obtained from liver disease patients.

It is of interest to note that among ZZ phenotypes with liver disease the α2-MG level is considerably lower. This reduction is unlikely to be attributed to liver disease since α2-MG levels are reported to be raised among liver disease patients. The biological significance is, however, not clear at the moment. Twumasi et al have suggested that increased complexing of α2-MG to elastase in ZZ patients could exacerbate the tissue destruction by elastase. Although the proof is inconclusive, these trends suggest the possibility of interrelated regulations of antiproteases in the normal, and deviations in this balance between antiproteases and proteases could lead to disease. Future experimental work is designed to test some of these possibilities.

References

Antiproteases and Down's syndrome in an Australian population


Requests for reprints to Miss H McPhee, Department of Genetics, University of Melbourne, Parkville, Victoria 3052, Australia.